Ibpi سبب نزوله من 13-الي 3

الموضوع في 'السوق الأمريكي للأوراق الماليه' بواسطة بن سويلم, بتاريخ ‏5 يوليو 2004.

  1. بن سويلم

    بن سويلم عضو جديد

    التسجيل:
    ‏11 أكتوبر 2003
    المشاركات:
    226
    عدد الإعجابات:
    0
    مكان الإقامة:
    الكويت
    الي شباب المنتدي لاهل الخبر سبب النزول هل هو فشل في الابحاث بخصوص منتج او دواء





    شكرا
     
  2. alnader2004

    alnader2004 عضو جديد

    التسجيل:
    ‏31 مارس 2004
    المشاركات:
    557
    عدد الإعجابات:
    0
    مكان الإقامة:
    قطر
    اخوي ياليت نبحث في اسباب النزول اذا كانت اسباب غير مبرره لهذا النزول نبي ندخل بثقلنا بهالسهم
     
  3. بن سويلم

    بن سويلم عضو جديد

    التسجيل:
    ‏11 أكتوبر 2003
    المشاركات:
    226
    عدد الإعجابات:
    0
    مكان الإقامة:
    الكويت
    اخوي النادر شكلها مغري

    اللي اعرفه انها شركه ادويه او من هالقبيل او بعد انه نزول اثر خبر يعني مو امسوين عليها سبلت يعني الضاهر فشل ابحاث او يمكن لها قضيه عموما انشالله نلقي احد من الشباب عنده الخبر قول امين



    شكرا
     
  4. aboyousef

    aboyousef عضو نشط

    التسجيل:
    ‏21 يونيو 2004
    المشاركات:
    1,730
    عدد الإعجابات:
    0
    مكان الإقامة:
    الرياض
    هلا

    الظاهر حسب معلوماتي المتواضعه هناك قضيه مرفوعة من المساهمين على الشركه وكذلك توقفها عن بعض الابحاث وهي شركة ادويه وفي رأيي يستحسن متابعتها .
     
  5. اول

    اول عضو محترف

    التسجيل:
    ‏14 ابريل 2004
    المشاركات:
    4,342
    عدد الإعجابات:
    0
    مكان الإقامة:
    السعودية- الرياض
    هذا خبر ياشباب وتمنى احد يترجمه ترجمه حقيقه وليست ترجمه مواقع

    BALA CYNWYD, Pa., July 2 /PRNewswire/ -- The following statement was issued today by the law firm of Schiffrin & Barroway, LLP:
    Notice is hereby given that a class action lawsuit was filed in the United States District Court for the Northern District of California on behalf of all purchasers of the common stock of IntraBiotics Pharmaceuticals, Inc. (Nasdaq: IBPI - News; "IntraBiotics" or the "Company") from September 5, 2003 through June 22, 2004, inclusive (the "Class Period").

    If you wish to discuss this action or have any questions concerning this notice or your rights or interests with respect to these matters, please contact Schiffrin & Barroway, LLP (Marc A. Topaz, Esq. or Stuart L. Berman, Esq.) toll free at 1-888-299-7706 or 1-610-667-7706, or via e-mail at info@sbclasslaw.com.

    The complaint charges IntraBiotics, Henry J. Fuchs, Detlef Albrecht, and David J. Tucker with violations of the Securities and Exchange Act of 1934 and Rule 10b-5 promulgated thereunder. More specifically, the Complaint alleges that the Company failed to disclose and misrepresented the following material adverse facts concerning the Company's wonder drug, iseganan, which were known to defendants or recklessly disregarded by them: (1) that iseganan was not safe and well-tolerated at therapeutically relevant doses when administered to the oral cavity; (2) that the drug caused a higher rate of ventilator- associated pneumonia ("VAP") and mortality as compared to placebo; (3) that despite knowing and/or recklessly disregarding the aforementioned facts, the defendants nevertheless raised capital through offerings of its common stock in order to portray to the market that iseganan was a viable marketable product that was on the "fast track" to FDA approval; and (4) that as a result of the above, the defendants statements concerning iseganan were lacking in any reasonable basis.

    On June 23, 2004, the Company announced that an independent data monitoring committee recommended to the Company that it discontinue its pivotal trial of iseganan for the prevention of VAP based on an interim analysis of the data. News of this shocked the market. Shares of IntraBiotics fell $9.45 per share or 69 percent, to close at $4.23 per share on unusually high trading volume.

    Plaintiff seeks to recover damages on behalf of class members and is represented by the law firm of Schiffrin & Barroway, which prosecutes class actions in both state and federal courts throughout the country. Schiffrin & Barroway is a driving force behind corporate governance reform, and has recovered in excess of a billion dollars on behalf of institutional and high net worth individual investors. For more information about Schiffrin & Barroway, or to sign up to participate in this action online, please visit http://www.sbclasslaw.com.

    If you are a member of the class described above, you may, not later than August 31, 2004 move the Court to serve as lead plaintiff of the class, if you so choose. A lead plaintiff is a representative party that acts on behalf of other class members in directing the litigation. In order to be appointed lead plaintiff, the Court must determine that the class member's claim is typical of the claims of other class members, and that the class member will adequately represent the class. Under certain circumstances, one or more class members may together serve as "lead plaintiff." Your ability to share in any recovery is not, however, affected by the decision whether or not to serve as a lead plaintiff. You may retain Schiffrin & Barroway, or other counsel of your choice, to serve as your counsel in this action.

    CONTACT: Schiffrin & Barroway, LLP
    Marc A. Topaz, Esq.
    Stuart L. Berman, Esq.
    Three Bala Plaza East, Suite 400
    Bala Cynwyd, PA 19004
    1-888-299-7706 (toll free) or 1-610-667-7706
    Or by e-mail at info@sbclasslaw.com